These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 2334412)
41. [Apolipoprotein E and its alleles in healthy subjects and in atherosclerosis]. Couderc R; Bailleul S Ann Biol Clin (Paris); 1998; 56(6):651-9. PubMed ID: 9853024 [TBL] [Abstract][Full Text] [Related]
43. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. Linton MF; Hasty AH; Babaev VR; Fazio S J Clin Invest; 1998 Apr; 101(8):1726-36. PubMed ID: 9541504 [TBL] [Abstract][Full Text] [Related]
44. New mutants of apolipoprotein E associated with atherosclerotic diseases but not to type III hyperlipoproteinemia. Yamamura T; Yamamoto A; Sumiyoshi T; Hiramori K; Nishioeda Y; Nambu S J Clin Invest; 1984 Oct; 74(4):1229-37. PubMed ID: 6480826 [TBL] [Abstract][Full Text] [Related]
45. Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes. Mamotte CD; Sturm M; Foo JI; van Bockxmeer FM; Taylor RR Am J Physiol; 1999 Mar; 276(3):E553-7. PubMed ID: 10070023 [TBL] [Abstract][Full Text] [Related]
46. Studies on the binding and degradation of human very-low-density lipoproteins by human hepatoma cell line HepG2. Dashti N; Wolfbauer G Biochim Biophys Acta; 1986 Feb; 875(3):473-86. PubMed ID: 3004589 [TBL] [Abstract][Full Text] [Related]
47. Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment. Moghadasian MH; Nguyen LB; Shefer S; Salen G; Batta AK; Frohlich JJ Metabolism; 2001 Jun; 50(6):708-14. PubMed ID: 11398149 [TBL] [Abstract][Full Text] [Related]
48. [Detection of apolipoproteins E5 and E7 by a widely used commercial ApoE IFE kit--evidence provided by genotyping]. Imura T; Kimura H; Murata S; Yamaguchi T; Kanou A; Nakashima M; Masunaga S; Yanagisawa R; Araki H; Matsuda T; Gejyo F Rinsho Byori; 1998 Mar; 46(3):289-93. PubMed ID: 9564770 [TBL] [Abstract][Full Text] [Related]
49. Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg136-->Cys) variant. Feussner G; Albanese M; Valencia A Atherosclerosis; 1996 Oct; 126(2):177-84. PubMed ID: 8902143 [TBL] [Abstract][Full Text] [Related]
50. Cholesterol lowering in low density lipoprotein receptor knockout mice overexpressing apolipoprotein E. Osuga J; Yonemoto M; Yamada N; Shimano H; Yagyu H; Ohashi K; Harada K; Kamei T; Yazaki Y; Ishibashi S J Clin Invest; 1998 Jul; 102(2):386-94. PubMed ID: 9664080 [TBL] [Abstract][Full Text] [Related]
52. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. Weisgraber KH; Innerarity TL; Harder KJ; Mahley RW; Milne RW; Marcel YL; Sparrow JT J Biol Chem; 1983 Oct; 258(20):12348-54. PubMed ID: 6313653 [TBL] [Abstract][Full Text] [Related]
53. A nonexchangeable apolipoprotein E peptide that mediates binding to the low density lipoprotein receptor. Mims MP; Darnule AT; Tovar RW; Pownall HJ; Sparrow DA; Sparrow JT; Via DP; Smith LC J Biol Chem; 1994 Aug; 269(32):20539-47. PubMed ID: 8051153 [TBL] [Abstract][Full Text] [Related]
54. Solubilization of apolipoprotein B and its specific binding by the cellular receptor for low density lipoprotein. Shireman R; Kilgore LL; Fisher WR Proc Natl Acad Sci U S A; 1977 Nov; 74(11):5150-4. PubMed ID: 200946 [TBL] [Abstract][Full Text] [Related]
55. Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Yamada N; Inoue I; Kawamura M; Harada K; Watanabe Y; Shimano H; Gotoda T; Shimada M; Kohzaki K; Tsukada T J Clin Invest; 1992 Feb; 89(2):706-11. PubMed ID: 1737858 [TBL] [Abstract][Full Text] [Related]
56. Enhancement of thyroxine entry into low density lipoprotein (LDL) receptor-competent fibroblasts by LDL: an additional mode of entry of thyroxine into cells. Benvenga S; Robbins J Endocrinology; 1990 Feb; 126(2):933-41. PubMed ID: 2105208 [TBL] [Abstract][Full Text] [Related]
57. Specific high-affinity binding of high density lipoproteins to cultured human skin fibroblasts and arterial smooth muscle cells. Biesbroeck R; Oram JF; Albers JJ; Bierman EL J Clin Invest; 1983 Mar; 71(3):525-39. PubMed ID: 6826722 [TBL] [Abstract][Full Text] [Related]
58. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. Knouff C; Hinsdale ME; Mezdour H; Altenburg MK; Watanabe M; Quarfordt SH; Sullivan PM; Maeda N J Clin Invest; 1999 Jun; 103(11):1579-86. PubMed ID: 10359567 [TBL] [Abstract][Full Text] [Related]
59. Functional unit of the low density lipoprotein receptor of fibroblasts: a 100,000-dalton structure with multiple binding sites. Innerarity TL; Kempner ES; Hui DY; Mahley RW Proc Natl Acad Sci U S A; 1981 Jul; 78(7):4378-82. PubMed ID: 6270675 [TBL] [Abstract][Full Text] [Related]
60. Human apolipoprotein E N-terminal domain displacement of apolipophorin III from insect low density lipophorin creates a receptor-competent hybrid lipoprotein. Fisher CA; Kiss RS; Francis GA; Gao P; Ryan RO Comp Biochem Physiol B Biochem Mol Biol; 1999 Apr; 122(4):447-51. PubMed ID: 10392457 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]